Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background and purpose: Midbrain atrophy is a characteristic feature of progressive supranuclear palsy (PSP), although it is unclear whether it is associated with the PSP syndrome (PSPS) or PSP pathology. The aim of the present study was to determine whether midbrain atrophy is a useful biomarker of PSP pathology, or whether it is only associated with typical PSPS. Methods: All autopsy-confirmed subjects were identified with the PSP clinical phenotype (i.e. PSPS) or PSP pathology and a volumetric MRI. Of 24 subjects with PSP pathology, 11 had a clinical diagnosis of PSPS (PSP-PSPS), and 13 had a non-PSPS clinical diagnosis (PSP-other). Three subjects had PSPS and corticobasal degeneration pathology (CBD-PSPS). Healthy control and disease control groups (i.e. a group without PSPS or PSP pathology) and a group with CBD pathology and corticobasal syndrome (CBD-CBS) were selected. The midbrain area was measured in all subjects. [Correction added on 21 June 2013, after first online publication: the abbreviation of corticobasal degeneration pathology was changed from CBD-PSP to CBD-PSPS.] Results: The midbrain area was reduced in each group with clinical PSPS (with and without PSP pathology). The group with PSP pathology and non-PSPS clinical syndromes did not show reduced midbrain area. Midbrain area was smaller in the subjects with PSPS than in those without PSPS (P < 0.0001), with an area under the receiver operator curve of 0.99 (0.88, 0.99). A midbrain area cut-point of 92 mm2 provided optimum sensitivity (93%) and specificity (89%) for differentiation. Conclusion: Midbrain atrophy is associated with the clinical presentation of PSPS, but not with the pathological diagnosis of PSP in the absence of clinical PSPS. This finding has important implications for the utility of midbrain measurements as diagnostic biomarkers for PSP pathology.

Original languageEnglish (US)
Pages (from-to)1417-1422
Number of pages6
JournalEuropean Journal of Neurology
Volume20
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Progressive Supranuclear Palsy
Mesencephalon
Atrophy
Biomarkers
Pathology
Primary Spontaneous Pneumothorax

Keywords

  • Midbrain
  • MRI
  • Neuropathology
  • Progressive supranuclear palsy
  • Tau

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology. / Whitwell, Jennifer Lynn; Jack, Clifford R Jr.; Parisi, Joseph E; Gunter, J. L.; Weigand, S. D.; Boeve, Bradley F; Ahlskog, J. E.; Petersen, Ronald Carl; Dickson, Dennis W; Josephs, Keith Anthony.

In: European Journal of Neurology, Vol. 20, No. 10, 10.2013, p. 1417-1422.

Research output: Contribution to journalArticle

@article{ca173cfa57ad492ba409157fafc76a38,
title = "Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology",
abstract = "Background and purpose: Midbrain atrophy is a characteristic feature of progressive supranuclear palsy (PSP), although it is unclear whether it is associated with the PSP syndrome (PSPS) or PSP pathology. The aim of the present study was to determine whether midbrain atrophy is a useful biomarker of PSP pathology, or whether it is only associated with typical PSPS. Methods: All autopsy-confirmed subjects were identified with the PSP clinical phenotype (i.e. PSPS) or PSP pathology and a volumetric MRI. Of 24 subjects with PSP pathology, 11 had a clinical diagnosis of PSPS (PSP-PSPS), and 13 had a non-PSPS clinical diagnosis (PSP-other). Three subjects had PSPS and corticobasal degeneration pathology (CBD-PSPS). Healthy control and disease control groups (i.e. a group without PSPS or PSP pathology) and a group with CBD pathology and corticobasal syndrome (CBD-CBS) were selected. The midbrain area was measured in all subjects. [Correction added on 21 June 2013, after first online publication: the abbreviation of corticobasal degeneration pathology was changed from CBD-PSP to CBD-PSPS.] Results: The midbrain area was reduced in each group with clinical PSPS (with and without PSP pathology). The group with PSP pathology and non-PSPS clinical syndromes did not show reduced midbrain area. Midbrain area was smaller in the subjects with PSPS than in those without PSPS (P < 0.0001), with an area under the receiver operator curve of 0.99 (0.88, 0.99). A midbrain area cut-point of 92 mm2 provided optimum sensitivity (93{\%}) and specificity (89{\%}) for differentiation. Conclusion: Midbrain atrophy is associated with the clinical presentation of PSPS, but not with the pathological diagnosis of PSP in the absence of clinical PSPS. This finding has important implications for the utility of midbrain measurements as diagnostic biomarkers for PSP pathology.",
keywords = "Midbrain, MRI, Neuropathology, Progressive supranuclear palsy, Tau",
author = "Whitwell, {Jennifer Lynn} and Jack, {Clifford R Jr.} and Parisi, {Joseph E} and Gunter, {J. L.} and Weigand, {S. D.} and Boeve, {Bradley F} and Ahlskog, {J. E.} and Petersen, {Ronald Carl} and Dickson, {Dennis W} and Josephs, {Keith Anthony}",
year = "2013",
month = "10",
doi = "10.1111/ene.12212",
language = "English (US)",
volume = "20",
pages = "1417--1422",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology

AU - Whitwell, Jennifer Lynn

AU - Jack, Clifford R Jr.

AU - Parisi, Joseph E

AU - Gunter, J. L.

AU - Weigand, S. D.

AU - Boeve, Bradley F

AU - Ahlskog, J. E.

AU - Petersen, Ronald Carl

AU - Dickson, Dennis W

AU - Josephs, Keith Anthony

PY - 2013/10

Y1 - 2013/10

N2 - Background and purpose: Midbrain atrophy is a characteristic feature of progressive supranuclear palsy (PSP), although it is unclear whether it is associated with the PSP syndrome (PSPS) or PSP pathology. The aim of the present study was to determine whether midbrain atrophy is a useful biomarker of PSP pathology, or whether it is only associated with typical PSPS. Methods: All autopsy-confirmed subjects were identified with the PSP clinical phenotype (i.e. PSPS) or PSP pathology and a volumetric MRI. Of 24 subjects with PSP pathology, 11 had a clinical diagnosis of PSPS (PSP-PSPS), and 13 had a non-PSPS clinical diagnosis (PSP-other). Three subjects had PSPS and corticobasal degeneration pathology (CBD-PSPS). Healthy control and disease control groups (i.e. a group without PSPS or PSP pathology) and a group with CBD pathology and corticobasal syndrome (CBD-CBS) were selected. The midbrain area was measured in all subjects. [Correction added on 21 June 2013, after first online publication: the abbreviation of corticobasal degeneration pathology was changed from CBD-PSP to CBD-PSPS.] Results: The midbrain area was reduced in each group with clinical PSPS (with and without PSP pathology). The group with PSP pathology and non-PSPS clinical syndromes did not show reduced midbrain area. Midbrain area was smaller in the subjects with PSPS than in those without PSPS (P < 0.0001), with an area under the receiver operator curve of 0.99 (0.88, 0.99). A midbrain area cut-point of 92 mm2 provided optimum sensitivity (93%) and specificity (89%) for differentiation. Conclusion: Midbrain atrophy is associated with the clinical presentation of PSPS, but not with the pathological diagnosis of PSP in the absence of clinical PSPS. This finding has important implications for the utility of midbrain measurements as diagnostic biomarkers for PSP pathology.

AB - Background and purpose: Midbrain atrophy is a characteristic feature of progressive supranuclear palsy (PSP), although it is unclear whether it is associated with the PSP syndrome (PSPS) or PSP pathology. The aim of the present study was to determine whether midbrain atrophy is a useful biomarker of PSP pathology, or whether it is only associated with typical PSPS. Methods: All autopsy-confirmed subjects were identified with the PSP clinical phenotype (i.e. PSPS) or PSP pathology and a volumetric MRI. Of 24 subjects with PSP pathology, 11 had a clinical diagnosis of PSPS (PSP-PSPS), and 13 had a non-PSPS clinical diagnosis (PSP-other). Three subjects had PSPS and corticobasal degeneration pathology (CBD-PSPS). Healthy control and disease control groups (i.e. a group without PSPS or PSP pathology) and a group with CBD pathology and corticobasal syndrome (CBD-CBS) were selected. The midbrain area was measured in all subjects. [Correction added on 21 June 2013, after first online publication: the abbreviation of corticobasal degeneration pathology was changed from CBD-PSP to CBD-PSPS.] Results: The midbrain area was reduced in each group with clinical PSPS (with and without PSP pathology). The group with PSP pathology and non-PSPS clinical syndromes did not show reduced midbrain area. Midbrain area was smaller in the subjects with PSPS than in those without PSPS (P < 0.0001), with an area under the receiver operator curve of 0.99 (0.88, 0.99). A midbrain area cut-point of 92 mm2 provided optimum sensitivity (93%) and specificity (89%) for differentiation. Conclusion: Midbrain atrophy is associated with the clinical presentation of PSPS, but not with the pathological diagnosis of PSP in the absence of clinical PSPS. This finding has important implications for the utility of midbrain measurements as diagnostic biomarkers for PSP pathology.

KW - Midbrain

KW - MRI

KW - Neuropathology

KW - Progressive supranuclear palsy

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=84883753333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883753333&partnerID=8YFLogxK

U2 - 10.1111/ene.12212

DO - 10.1111/ene.12212

M3 - Article

C2 - 23746093

AN - SCOPUS:84883753333

VL - 20

SP - 1417

EP - 1422

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 10

ER -